anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND AIMS: Adipose tissue (AT) serves as a vital energy storage site and plays a pivotal role in metabolic regulation, exhibiting a high response to insulin. Impairment in this response may closely associate with obesity, and NFAT (nuclear factor of activated T cells) family genes may be involved in the process. However, human data linking NFAT and AT remains elusive. The aim of this study was to assess the expression of NFAT family genes and markers of adipogenesis in subcutaneous adipose tissue (SAT) among normal-weight and overweight/obese individuals before and after weight loss, in relation to insulin sensitivity.
METHODS AND RESULTS: The study included 45 participants, 15 normal-weight (control group) and 30 overweight or obese, who underwent a 12-week dietary intervention (DI) program. Before and after the program hyperinsulinemic-euglycemic clamp and SAT biopsy were conducted. Before DI, a positive correlations was observed in the expression of NFATc1, NFATc4, and NFAT5 with insulin sensitivity. The expression of NFAT family genes and markers of adipogenesis in SAT was lower in individuals with overweight or obesity compared to normal-weight. Additionally, a positive correlation was noted between NFAT family genes and adipogenesis markers both before and after weight loss. Following the DI program, there was an increase in the expression of NFATc3, NFATc4, and NFAT5 in SAT.
CONCLUSION: Decreased SAT expression of NFAT genes in obesity is partly reversed in response to weight loss. NFAT genes in SAT are associated with insulin sensitivity and adipogenesis. Registration number for clinical trial: NCT01393210.
<P>PROBLEM TO BE SOLVED: To provide a mineral extract extracted in water, and containing mineral component derived from livestock industry bone dust, especially a natural mineral extract extracted in water, and containing silicon in mineral component.  <P>SOLUTION: This mineral extract extracted in water contains mineral component derived from livestock industry bone dust and has pH10-12. The natural mineral extract extracted in water is obtained by using as livestock industry bone dust, bone dust which is made by boiling raw material livestock industry bone with a high-pressure iron pot followed by drying, and baking the dried bone with a high-temperature iron pot of >1,000°C followed by pulverizing, and using as water for water extraction, purified water in which ozone-containing air is absorbed. Furthermore, the natural mineral extract contains silicon in the mineral component. The purified water in which ozone-containing air is absorbed is obtained by absorbing ozone-containing air in pH6.8-7.8 purified water which is obtained by treating water with ion exchange resin and/or activated carbon, and is adjusted to pH8.0-8.5.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Lipid-protein-sugar particles (LPSPs) are provided as a vehicle for drug delivery. Any therapeutic, diagnostic, or prophylatic agent may be encapsulated in a lipid-protein-sugar matrix to form microparticles. Preferably the diameter of the LPSP ranges from 50 nm to 10 micrometers. The particles may be prepared using any known lipid (e.g., DPPC), protein (e.g., albumin), or sugar (e.g., lactose). Methods of preparing and administering the particles are also provided. Methods of providing a nerve block are also provided by administering LPSPs with a local anesthetic (e.g., bupivacaine) within the vicinity of a nerve.
PURPOSE: To enhance stability of a solid pharmaceutical compsn. containing a pharmaceutically active deriv. of vitamin D2 and vitamin D3 as active component. CONSTITUTION: This solid pharmaceutical compsn. contains at least (a), (b) and (c) in the following components (a), (b), (c) and (d). The components are (a) at least one kind of active component selected from pharmaceutically active derivs. of vitamin D2 and vitamin D3, (b) at least one kind of pharmaceutically acceptable antioxidant, (c) at least one kind of pharmaceutically acceptable polyoxyalkyl stabilizer, and (d) at least one kind of pharmaceutically acceptable solid excipient or carrier in an enough amt. to impart solid property to the compsn.
This study will evaluate uptake of the hepatobiliary magnetic resonance imaging (MRI) contrast agent gadolinium ethoxybenzyl dimeglumine, or Eovist (Bayer Imaging, Wayne, NJ) within hepatocellular carcinomas (HCCs) at delayed, 24 hour imaging. The recommended dose of Eovist is 0.1 mL/kg, or 0.025 mmol/kg.
Hydrocodone, like all narcotics, may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Such tasks should be avoided while taking this product.

Alcohol and other CNS depressants may produce an additive CNS depression, when taken with this combination product, and should be avoided.

Hydrocodone may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.

Physicians should instruct patients and caregivers to read the patient information leaflet, which appears as the last section of the labeling.
PURPOSE:A cosmetic, containing an extract component prepared by extracting the root of Salvia miltiorrhiza Bunge, etc. as an active constituent, having improved skin beautifying effect and beautifying and whitening effect and humectant effect and capable of producing effect, e.g. tension, gloss, smoothness, etc. of the skin by using in cream, toilet water, etc. CONSTITUTION:A cosmetic containing an extract component prepared by extracting the dried root of Salvia miltorrhiza Bunge or Salvia przewalskii Maxim. var. mandarinorum Stib. as an active constituent. The Salvia miltiorrhiza Bunge or Salvia przewalskii Maxim. var. mandarinorum Stib. is a perennial plant belonging to the genus Labiatae. The extract thereof is obtained by cutting the dried root of the Salvia miltiorrhiza Bunge or Salvia przewalskii Maxim. var. mandarinorum Stib. to fragements having <=2cm thickness or powder with a cutter, and extracting the resultant fragments or powder with an organic solvent, e.g. ethyl acetate or acetone, and/or water. In using as a cosmetic, a water-soluble high polymer, e.g. polypeptide or casein, is preferably further incorporated with the above-mentioned active constituent, because the percutaneous absorption is increased. The amount of the active constituent to be incorporated is preferably 0.1-5wt%.
The current recommended triple regimen for H. pylori treatment provides unacceptable low success rates because of high antibiotic resistance and poor compliance. Dual therapy had been used before and can be modified to get good eradication rate. The aim of our trial is to evaluate and compare the efficacy and safety of dual therapy regimens for initial treatment of H. pylori infection. A total of forty patients with non-ulcer dyspepsia and H. pylori infection were randomized to receive either Rabeprazole 10 mg b.i.d. and Amoxicillin 1000 mg t.i.d., for 14 days (R10A), or high-dose Rabeprazole 20 mg twice a day (b.i.d.) and Amoxicillin 1000 mg three times a day (t.i.d) (R20A) for 14 days. H. pylori strains were isolated and antibiotic resistance was measured by the twofold agar dilution method. H. pylori eradication was assessed by 13C-urea breath test at 4 weeks after treatment.
Participants will receive 0.5 mg of ICS (budesonide as Pulmicort Respules®) once a day at night, except during respiratory tract illnesses. During respiratory tract illnesses, participants will receive placebo each morning and 0.5 mg of budesonide each night for 7 days.
<P>PROBLEM TO BE SOLVED: To provide a stable nonaqueous base containing a polyhydric alcohol with a simple method.  <P>SOLUTION: The nonaqueous base consists of or contains a polyhydric alcohol and a hydroxy group-containing liquid ester oil. The polyhydric alcohol and the liquid ester oil are each (A) or (B): (A) a polyhydric alcohol having two hydroxy groups in the molecule and a hydroxy group-containing liquid ester oil with an IOB of 0.150-0.480. (B) a polyhydric alcohol having three or more hydroxy groups in the molecule and a hydroxy group-containing liquid ester oil with an IOB of 0.200-0.420. A nonaqueous external preparation consisting of or containing the nonaqueous base is also presented.  <P>COPYRIGHT: (C)2004,JPO
The invention discloses a shampoo with traditional Chinese medicine. The traditional Chinese medicine is prepared from, by weight, 20-30 parts of rice powder, 10-20 parts of musk, 10-20 parts of radix trichosanthis, 10-20 parts of cacti and 10-20 parts of acanthopanax. The rice powder and the four kinds of traditional Chinese medicine are added into a common shampoo to prepare the shampoo with the traditional Chinese medicine. The shampoo with the traditional Chinese medicine can accelerate cerebral blood circulation and improve sufficient nutrition, thereby increasing cerebral circulation volume, effectively resisting cerebral hypoxia state, promoting cerebral cell energy metabolism and neurotransmitter in brain, and ensuring that the medicine directly acts on cerebral cortex. The shampoo can rapidly remove oil and scurf in hair, remove excessive oil secretion, enable hazardous substance damaging hair to be eliminated and keep the hair pitch-black, glossy and smooth, and has the effects of removing oil and scurf, relieving itch in head, preventing hair loss and the like. Compared with a common shampoo on the market, the shampoo with the traditional Chinese medicine has the advantages of being environmentally friendly, nourishing and protecting hair, not damaging hair and the like.
PURPOSE:To provide a plaster for adhesive salve preparation having improved long-term preservation stability of the drug in the plaster, by compounding sesamol to a plaster composed of a rubber-based adhesive substance. CONSTITUTION:A plaster for adhesive salve preparation composed of a rubber- based adhesive mixture such as natural rubber, a synthetic rubber or their mixture, etc. is compounded with about 0.002-5wt%, especially about 0.01-2wt%, based on the whole plaster, of sesamol. The additive is effective to prevent the lowering of the drug action in the plster, especially action of a compound containing phenolic OH, e.g. a salicyclic acid derivative and an amino compound such as diphenhydramine, etc. which exhibits remarkable decrease of the content in said plaster. Sesame oil containing about 0.1wt% of sesamol or sesamoline produces sesamoline by hydrolysis can be used in place of sesamol, and a third component such as tackifier, etc. can be compounded to the above plaster.
An immigrant woman in her 60s with a complex medical history and remote occupational exposure to patients with tuberculosis (TB) presented with abdominal pain, early satiety, bloating and weight loss. Physical exam showed abdominal distention and ascites. Diagnostic paracentesis revealed low serum ascites albumin gradient and elevated ascitic lymphocytic count. However, fluid cytology, bacterial and mycobacterial cultures were negative. An interferon-gamma release assay for TB was indeterminate. MRI of the abdomen and pelvis showed a thickened endometrial stripe. Endometrial biopsy demonstrated non-caseating granulomatous endometritis. No organisms were identified on Grocott methenamine silver or acid-fast bacilli special stains. A tissue block from the endometrial biopsy submitted for DNA sequencing was positive for mycobacterium tuberculosis (MTB) complex Urine mycobacterial cultures were obtained and the patient was started on isoniazid, rifampin, ethambutol and pyrazinamide, with significant improvement in her symptoms. Urine mycobacterial cultures were eventually positive for pansusceptible MTB.
HIV/STI and drug abuse remain significant public health priorities in the US and youth are disproportionately affected. Youth between the ages of 15 - 24 constitute 25% of the sexually experienced population, yet account for 46% and 50% of HIV infections and new STIs, respectively. National surveillance data indicate that youth disproportionately engage in HIV/STI risk behaviors, including condomless sex and licit and illicit drug use, which increase their risk for HIV/STI infection. Despite the disproportionately high rates of HIV/STI infection and risk behaviors in youth, fewer than 14% report having ever been tested for HIV and many are not routinely screened for asymptomatic STIs as recommended by the Center for Disease Control. In Southeast Michigan, HIV/STI are disproportionately high. To address these significant public health concerns, a mobile-health (mHealth) intervention was developed for health clinic settings. The proposed research aims to develop a cross-platform and universal version of S4E. The cross-platform and universal version of S4E will be compatible with both IOS and Android operating systems, and multiple mobile devices, aimed at providing adolescents with ongoing access to the intervention once they leave the clinic. The proposed research will also evaluate the preliminary efficacy of S4E to improve HIV/STI testing and reduce HIV/STI risk behaviors in a clinic sample (n=100) of at-risk youth ages 14-21 living in Southeast Michigan by conducting a Stage I RCT to examine the preliminary efficacy of S4E, relative to Usual Care, among a sample of 100 at-risk youth over six months.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The rates of adverse reactions given below were reported in a randomized, multicenter, prospective, vehicle and active controlled clinical trial in adult subjects with plaque psoriasis. Subjects applied WYNZORA Cream, calcipotriene/betamethasone dipropionate topical suspension, 0.005%/0.064% or vehicle once daily for 8 weeks. The mean weekly dose of WYNZORA Cream was 33.8 g. A total of 342 subjects were treated with WYNZORA Cream, 337 with calcipotriene/betamethasone dipropionate topical suspension, 0.005%/0.064% and 115 with vehicle. The majority of subjects were White (87%) and male (62%). Approximately 72% were non-Hispanic/Latino. The mean age was 52 years and ages ranged from 18 to 89 years.

The most common adverse reactions reported by ≥1% of subjects treated with WYNZORA Cream and more frequently than vehicle are presented in Table 1 below.
The kit has a care product e.g. mascara inside a container. The product has a thermal profile with a fusion pick having width of mid-height less than or equal to 10 degree Celsius. A heating unit (53) carries the product before, during or after its application to a temperature greater or equal to its fusion point. The heating unit is associated to an applying device and the container. An independent claim is also included for a refill with a make-up and care products e.g. mascara conditioning and applying kit.
During the past 6 years, our study team investigated the neural mechanism of typically-occurring convergence insufficiency (TYP-CI), the most common binocular vision disorder in children and young adults (3.4% to 12.7%5-11). We conducted the only randomized clinical trial (RCT) integrating objective eye movement and fMRI outcome measures, achieving 100% planned enrollment and retention of 100 young adults. Our results localized the reduction in functional activity for TYP-CI compared to controls within the oculomotor vermis (OVM) and the cuneus. Functional activity in the OVM and cuneus was significantly correlated to convergence peak velocity providing the first mechanistic identification of these deficits that create significant burden to those afflicted. Our longitudinal results discovered that the neural mechanistic change stimulated by office-based vergence /accommodative therapy (OBVAT) is an increase in the frontal eye field (FEF) and thalamus functional activity. Increased functional activity from the FEF and thalamus significantly correlates to convergence peak velocity. Results are leading to personalized point-of-care therapies remediating the debilitating symptoms for TYP-CI patients. While our research and results of other RCTs show that OBVAT is the most effective treatment for remediating symptoms and improving vision function in both TYP-CI children and adults, none of these participants had a history of head injury, a pathology that has been linked to CI. Our research team has demonstrated that the prevalence of CI is higher (38% to 49%) in children and adults with persistent post-concussive symptoms (PPCS-CI), than in the non-concussed population. Currently, there is no validated treatment for PPCS-CI. This difference in prevalence, mode of onset (longstanding versus sudden onset), and severity of the condition has led to a debate about whether the diagnostic and management procedures effective for TYP-CI should be utilized for PPCS-CI, and strongly suggests that new research is needed to optimize PPCS-CI management. We are uniquely positioned to provide answers to these questions by building on our work establishing the neurofunctional mechanism of TYP-CI and OBVAT administered to TYP-CI. Such research is of great importance because PPCS-CI is associated with debilitating visual symptoms impacting the return to school/sports, work, or driving. We have identified three significant gaps for the treatment of PPCS-CI that must be addressed to determine its most effective management. First, given the obvious differences in etiology, are there significant differences between TYP-CI and PPCS-CI related to objective eye movement measures (peak velocity, final amplitude, and repeatability) due to underlying neural mechanistic differences? Second, what is the underlying neural mechanism of OBVAT for PPCS-CI compared to TYP-CI? Third, how effective is OBVAT for PPCS-CI and is the dosage of administration different than TYP-CI? This renewal addresses these gaps in clinical science.
Severe aortic stenosis (AS) is a frequent valvular heart disease in the elderly with a prevalence of 4 to 10% and a mean survival of only 0.5 to 5 years if left untreated. Transcatheter aortic valve implantation (TAVI) has evolved as standard of care for high-, intermediate and potentially even low surgical risk candidates due to a lower perioperative risk compared to surgical aortic valve replacement (SAVR). Despite its relative safety compared to SAVR, embolic events originating from the calcified valve and leading to ischemic stroke and acute renal injury are major complications following TAVI in the acute and subacute period, and are associated with increased morbidity including cognitive decline and mortality. While cerebral embolic protection devices (CEPD) such as the Sentinel® CEPD (Boston Scientific) were designed to reduce the burden of cerebral embolic events, their impact on clinical events has yet to be determined, and other prophylactic options are currently not available. Ischemia/reperfusion injury (IRI) is a key pathophysiological mechanism involved in cerebral and renal embolic events after TAVI resulting in activation of endothelial cells, the contact activation and the complement system and attraction of neutrophils to the site of injury. In this regard, recombinant human C1 esterase inhibitor (rhC1INH, conestat alfa), a potent inhibitor of the complement and the contact system has been shown to reduce the size of cerebral ischemic damage and of renal injury in experimental IRI models, and has successfully been investigated in a pilot study of acute kidney injury following the administration of contrast media. The aim of the current trial is to assess the safety and efficacy of conestat alfa (Ruconest®, Pharming Technologies B.V.) on renal and cerebral ischemic events in patients undergoing TAVI for severe symptomatic AS compared to placebo.
This is a multicenter, double blinded, pilot randomized clinical trial that will be conducted at UTMB Health, and other participating sites. Each participating site will obtain IRB approval. Women with symptomatic, stage II to IV Pelvic organ prolapse (POP) who plan colpocleisis will be approached to participate. Using the study protocol inclusion and exclusion criteria, patient's eligibility will be determined. All eligible subjects will provide the written informed consent before any research data is collected. All screening assessment will be completed at a preoperative, in-person, clinic visit, and within 60 days of surgery. The subject will then undergo randomization to the local TXA, or Vasopressin, or NS group with the total sample size of 36 female subjects (12 per group). Concomitant procedures for POP or urinary incontinence are permitted and will be based upon the operating surgeons' standard clinical practice and best clinical judgement. The anesthesia team is responsible for preparing the study agents, monitoring intraoperative cardiovascular parameters (blood pressure and heart rate) as well as adverse events, and determining the blood transfusion if needed. Subsequently, the subject will have postoperative follow up at 2 weeks and 6 weeks
Acetaminophen is a widely used antipyretic and analgesic drug, and its overdose is the leading cause of drug-induced acute liver failure. This study aimed to investigate the effect and mechanism of Lacticaseibacillus casei Shirota (LcS), an extensively used and highly studied probiotic, on acetaminophen-induced acute liver injury. C57BL/6 mice were gavaged with LcS suspension or saline once daily for 7 days before acute liver injury was induced via intraperitoneal injection of 300 mg/kg acetaminophen. The results showed that LcS significantly decreased acetaminophen-induced liver and ileum injury, as demonstrated by reductions in the increases in aspartate aminotransferase, total bile acids, total bilirubin, indirect bilirubin, and hepatic cell necrosis. Moreover, LcS alleviated acetaminophen-induced intestinal mucosal permeability, decreased serum IL-1α and lipopolysaccharide levels, and elevated serum eosinophil chemokine (eotaxin) and hepatic glutathione levels. Furthermore, analysis of the gut microbiota and metabolome showed that LcS reduced the acetaminophen-enriched levels of Cyanobacteria, Oxyphotobacteria, long-chain fatty acids, cholesterol, and sugars in the gut. Additionally, the transcriptomic and proteomic results showed that LcS mitigated the decrease in metabolic and immune pathways as well as glutathione formation during acetaminophen-induced acute liver injury. This is the first study showing that pretreatment with LcS alleviates acetaminophen-enriched acute liver injury, and it provides a reference for the application of LcS.IMPORTANCEAcetaminophen is the most frequently used antipyretic analgesic worldwide. As a result, overdoses easily occur and lead to drug-induced acute liver injury, which quickly progresses to liver failure with a mortality of 60%-80% if not corrected in time. The current emergency treatment for overused acetaminophen needs to be administered within 8 hours to avoid liver injury or even liver failure. Therefore, developing preventive strategies for liver injury during planned acetaminophen medication is particularly important, preferably nonpharmacological methods. Lacticaseibacillus casei Shirota (LcS) is a famous probiotic that has been used for many years. Our study found that LcS significantly alleviated acetaminophen-induced acute liver injury, especially acetaminophen-induced liver injury toward fulminant hepatic failure. Here, we elucidated the function and potential mechanisms of LcS in alleviating acetaminophen-induced acute liver injury, hoping it will provide preventive strategies to people during acetaminophen treatment.